Erik A Imel1, Amie K Gray2, Leah R Padgett2, Michael J Econs2. 1. Indiana University School of Medicine, Department of Medicine, USA; Indiana University School of Medicine, Department of Pediatrics, USA. Electronic address: eimel@iupui.edu. 2. Indiana University School of Medicine, Department of Medicine, USA.
Abstract
BACKGROUND: Excess fibroblast growth factor 23 (FGF23) causes hypophosphatemia in autosomal dominant hypophosphatemic rickets (ADHR) and X-linked hypophosphatemia (XLH). Iron status influences C-terminal FGF23 (incorporating fragments plus intact FGF23) in ADHR and healthy subjects, and intact FGF23 in ADHR. We hypothesized that in XLH serum iron would inversely correlate to C-terminal FGF23, but not to intact FGF23, mirroring the relationships in normal controls. METHODS: Subjects included 25 untreated outpatients with XLH at a tertiary medical center and 158 healthy adult controls. Serum iron and plasma intact FGF23 and C-terminal FGF23 were measured in stored samples. RESULTS: Intact FGF23 was greater than the control mean in 100% of XLH patients, and >2SD above the control mean in 88%, compared to 71% and 21% respectively for C-terminal FGF23. In XLH, iron correlated negatively to log-C-terminal FGF23 (r=-0.523, p<0.01), with a steeper slope than in controls (p<0.001). Iron was not related to log-intact FGF23 in either group. The log-ratio of intact FGF23 to C-terminal FGF23 was higher in XLH (0.00±0.44) than controls (-0.28±0.21, p<0.01), and correlated positively to serum iron (controls r=0.276, p<0.001; XLH r=0.428, p<0.05), with a steeper slope in XLH (p<0.01). CONCLUSION: Like controls, serum iron in XLH is inversely related to C-terminal FGF23 but not intact FGF23. XLH patients are more likely to have elevated intact FGF23 than C-terminal FGF23. The relationships of iron to FGF23 in XLH suggest that altered regulation of FGF23 cleaving may contribute to maintaining hypophosphatemia around an abnormal set-point.
BACKGROUND: Excess fibroblast growth factor 23 (FGF23) causes hypophosphatemia in autosomal dominant hypophosphatemic rickets (ADHR) and X-linked hypophosphatemia (XLH). Iron status influences C-terminal FGF23 (incorporating fragments plus intact FGF23) in ADHR and healthy subjects, and intact FGF23 in ADHR. We hypothesized that in XLH serum iron would inversely correlate to C-terminal FGF23, but not to intact FGF23, mirroring the relationships in normal controls. METHODS: Subjects included 25 untreated outpatients with XLH at a tertiary medical center and 158 healthy adult controls. Serum iron and plasma intact FGF23 and C-terminal FGF23 were measured in stored samples. RESULTS: Intact FGF23 was greater than the control mean in 100% of XLHpatients, and >2SD above the control mean in 88%, compared to 71% and 21% respectively for C-terminal FGF23. In XLH, iron correlated negatively to log-C-terminal FGF23 (r=-0.523, p<0.01), with a steeper slope than in controls (p<0.001). Iron was not related to log-intact FGF23 in either group. The log-ratio of intact FGF23 to C-terminal FGF23 was higher in XLH (0.00±0.44) than controls (-0.28±0.21, p<0.01), and correlated positively to serum iron (controls r=0.276, p<0.001; XLH r=0.428, p<0.05), with a steeper slope in XLH (p<0.01). CONCLUSION: Like controls, serum iron in XLH is inversely related to C-terminal FGF23 but not intact FGF23. XLHpatients are more likely to have elevated intact FGF23 than C-terminal FGF23. The relationships of iron to FGF23 in XLH suggest that altered regulation of FGF23 cleaving may contribute to maintaining hypophosphatemia around an abnormal set-point.
Authors: Erik A Imel; Munro Peacock; Amie K Gray; Leah R Padgett; Siu L Hui; Michael J Econs Journal: J Clin Endocrinol Metab Date: 2011-08-31 Impact factor: 5.958
Authors: Shoji Ichikawa; Geneviève Baujat; Aksel Seyahi; Anastasia G Garoufali; Erik A Imel; Leah R Padgett; Anthony M Austin; Andrea H Sorenson; Zagorka Pejin; Vicken Topouchian; Pierre Quartier; Valerie Cormier-Daire; Michele Dechaux; Fotini Ch Malandrinou; Panagiotis N Singhellakis; Martine Le Merrer; Michael J Econs Journal: Am J Med Genet A Date: 2010-04 Impact factor: 2.802
Authors: Shoji Ichikawa; Erik A Imel; Mary L Kreiter; Xijie Yu; Donald S Mackenzie; Andrea H Sorenson; Regina Goetz; Moosa Mohammadi; Kenneth E White; Michael J Econs Journal: J Clin Invest Date: 2007-09 Impact factor: 14.808
Authors: Shoji Ichikawa; Andrea H Sorenson; Anthony M Austin; Donald S Mackenzie; Timothy A Fritz; Akira Moh; Siu L Hui; Michael J Econs Journal: Endocrinology Date: 2009-02-12 Impact factor: 4.736
Authors: Erica L Clinkenbeard; Emily G Farrow; Lelia J Summers; Taryn A Cass; Jessica L Roberts; Christine A Bayt; Tim Lahm; Marjorie Albrecht; Matthew R Allen; Munro Peacock; Kenneth E White Journal: J Bone Miner Res Date: 2014-02 Impact factor: 6.741
Authors: Shiguang Liu; Rong Guo; Leigh G Simpson; Zhou-Sheng Xiao; Charles E Burnham; L Darryl Quarles Journal: J Biol Chem Date: 2003-07-21 Impact factor: 5.157
Authors: Rakesh Malhotra; Ronit Katz; Andrew Hoofnagle; Andrew Bostom; Dena E Rifkin; Ruth Mcbride; Jeffrey Probstfield; Geoffrey Block; Joachim H Ix Journal: Clin J Am Soc Nephrol Date: 2017-12-05 Impact factor: 8.237
Authors: Erik A Imel; Ziyue Liu; Amie K McQueen; Dena Acton; Anthony Acton; Leah R Padgett; Munro Peacock; Michael J Econs Journal: Bone Date: 2016-03-08 Impact factor: 4.398
Authors: Erik A Imel; Ziyue Liu; Melissa Coffman; Dena Acton; Rakesh Mehta; Michael J Econs Journal: J Bone Miner Res Date: 2019-10-25 Impact factor: 6.741
Authors: C Liu; X Li; Z Zhao; Y Chi; L Cui; Q Zhang; F Ping; X Chai; Y Jiang; O Wang; M Li; X Xing; W Xia Journal: Osteoporos Int Date: 2020-09-30 Impact factor: 4.507